RESISTANT HYPERTENSION IN A PATIENT WITH METABOLIC SYNDROME
https://doi.org/10.20996/1819-6446-2016-12-6-692-697
Abstract
Clinical case of resistant hypertension in a patient with metabolic syndrome is presented. Features of hypertension in metabolic syndrome and features of metabolic syndrome in women of pre- and postmenopausal age are also considered. Understanding the features of metabolic syndrome in women, as well as features of hypertension and metabolic syndrome will improve the results of treatment in patients with resistant hypertension.
About the Authors
O. M. Drapkina
State Research Center for Preventive Medicine
Russian Federation
Russian Federation
Oxana M. Drapkina - MD, PhD, Professor, Corresponding Member of the Russian Academy of Sciences, Deputy Director for Research and Clinical Work, Head of Department of Fundamental and Applied Aspects of Obesity.
Petroverigsky per., 10, Moscow, 101990
J. S. Sibgatullina
I.M. Sechenov First Moscow State Medical University
Russian Federation
Julia S. Sibgatullina - MD, Resident, Chair of Propaedeutics of Internal Medicine
Russian Federation
Julia S. Sibgatullina - MD, Resident, Chair of Propaedeutics of Internal Medicine
References
1. Mathers C., Stevens G., Mascarenhas M. Global health risks: mortality and burden of disease attributable to selected major risks. Geneva, Switzerland: World Health Organization; 2009
2. Kearney P.M., Whelton M., Reynolds K., et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365(9455):217-23.
3. Boytsov S.A., Balanova J.A., Shalnova S.A. Arterial hypertension among people aged25-64: prevalence, awareness,treatment and control. According to ESSE study. Kardiovaskulyarnaya Terapiya i Profilaktika 2014;14(4):4-14. (In Russ.) [Бойцов С.А., Баланова Ю.А., Шальнова С.А. Артериальная гипертония среди лиц 25-64 лет: распространенность, осведомленность, лечение и контроль. По материалам исследования ЭССЕ. Кардиоваскулярная Терапия и Профилактика. 2014;14(4):4-14].
4. Oganov R.G., Timofeev T.N., Koltunov I.E. Epidemiology of arterial hypertension in Russia. The federal monitoring results of 2003-2010. Kardiovaskulyarnaya Terapiya i Profilaktika. 2011;10(1):9-13. (In Russ.) [Оганов Р.Г., Тимофеева Т.Н., Колтунов И.Е. Эпидемиология артериальной гипертонии в России. Результаты федерального мониторинга 2003-2010 гг. Кардиоваскулярная Терапия и Профилактика. 2011;10(1):9-13].
5. Calhoun D.A., Jones D., Textor S., et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation. 2008;117(25):e510-26.
6. Lloyd-Jones D.M., Larson M.G., Leip E.P., et al. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation. 2002;106(24):3068-72.
7. Cushman W.C., Ford C.E., Cutler J.A., et al. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich). 2002;4(6):393-404.
8. Preobrazhensky D.V., Sidorenko B.A., Dedov J.S., et al. Lercanidipine - a new generation calcium antagonist of the third: Clinical Pharmacology and application experience in the treatment of hypertension. Russkiy Mediinskiy Zhurnal. 2006; 20: 14-7. (In Russ.) [Преображенский Д.В., Сидоренко Б.А., Дедова И.С., Шаипова А.М., Тарыкина Е.В. Лерканидипин – новый антагонист кальция третьего поколения: клиническая фармакология и опыт применения при лечении артериальной гипертензии. Русский Медиинский Журнал. 2006;20:14-7].
9. Alberti K.G., Eckel R.H., Grundy S.M. et al. Harmonizing the metabolic syndrome: a joint interim statement of the International diabetes federation task force on epidemiology and preventio. Circulation. 2009;120:1640-5.
10. Massiera F., Bloch-Faure M., Ceiler D. et al. Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation. FASEB J. 2001;15(14):2727-9.
11. Pieterse C., Schutte A.E., Mels C. et al. Carotid cross-sectional wall area is significantly associated with serum leptin levels, independent of body mass index: the SABPA study. Hypertens Res. 2012;35(12):1185-92.
12. LiebW., Pencina M.J., Lanier K.J. et al. Association of parental obesity with concentrations of select systemic biomarkers in nonobese offspring: the Framingham Heart Study. Diabetes. 2009;58(1): 134-7.
13. Ahimastos A.A. Ramipril reduces large-artery stiffness in peripheral arterial disease and promotes elastogenic remodeling in cell culture. Hypertension. 2005;45:1194-9.
14. Belotserkotseva L.D., Kovalenko L.V., Korneeva E.V., et al. Features of the metabolic syndrome in women in different periods of life. Pathogenesis, clinical manifestations, diagnosis, treatment. Moscow: Akademiya Estestvoznaniya; 2010. (In Russ.) [Белоцеркоцева Л.Д., Коваленко Л.В., Корнеева Е.В., и др. Особенности метаболического синдрома у женщин в различные периоды жизни: патогенез, клиника, диагностика, лечение. М.: Академия Естествознания; 2010].
15. American diabetes association. Standards of medical care in diabetes - 2015. Diabetes Care. 2015;38 Suppl 1:1-93.
16. Machowska A., Juszczak K., Novak P. et al. The natriuretic peptide neurohormonal system modulation by vasopeptidase inhibitors-the novel therapeutical approach of hypertension treatment. Folia Med Cracov 2009; 50(3-4): 35-42
17. Bryan Williams, Tom MacDonald and Morris Brown on behalf of the PATHWAY Investigators. The Prevention And Treatment of Hypertension With Algorithm based therapY PATHWAY Optimal Treatment of Drug Resistant Hypertension PATHWAY-2 Principal Results 2015.
Review
For citations:
Drapkina O.M., Sibgatullina J.S. RESISTANT HYPERTENSION IN A PATIENT WITH METABOLIC SYNDROME. Rational Pharmacotherapy in Cardiology. 2016;12(6):692-697. (In Russ.) https://doi.org/10.20996/1819-6446-2016-12-6-692-697
Views: 666
Email this article 